Pear Bio - Cancer therapeutics

Pear Bio monitors cancer progression of patient-derived tumor samples against potential treatment options with a microtumor technology that recreates core parts of the human tumor microenvironment for accurate lab testing. With the aid of computer vision algorithms, they measure the impact each treatment has on stopping cancer in its tracks and eliminating the tumor.

Headquarters

Headquarters

London, England

Founded

Founded

2017

Disease Area

Disease Area

Oncology

Solution

Solution

Drug Discovery

Company Stage

Company Stage

Series A+

Clinical Development in Immuno-Oncology

Clinical development in immuno-oncology has unique challenges that make it difficult to position drugs effectively. Traditional pharmacokinetics (PK) and pharmacodynamics (PD) models often fall short in predicting the efficacy and safety of immunotherapies. The systemic and intratumoral immune effects do not consistently align with standard dose-toxicity-efficacy relationships that are well-understood in cytotoxic therapies. This discrepancy often leads to the failure of promising drugs in the clinical development stage (Kort et al.,2016).

Another challenge is the identification of adverse events specifically related to the immune system. These events can be unique to immuno-oncology drugs and require specialized monitoring and management strategies (Chen, 2013).

Results

Neuroute's analysis covered 8 indications and assessed the performance of 1,790 clinical studies, providing Pear Bio with actionable insights into the current landscape of clinical development in immuno-oncology. It helped Pear Bio to identify new trends in successful clinical trial designs, thereby enabling them to develop more robust strategies for future trials.

8

Indications

1,790

Studies Analyzed

Process

By leveraging these databases, Neuroute was able to provide a more holistic view of the clinical trial landscape:

ClinicalTrials.gov. Clinical trial data accessed through semantic search using large language models.

Central Intelligence Agency. Ethnicity and language data.The World Factbook.

Institute for Health Metrics and Evaluation (IHME) Disease prevalence data.

Center Watch Destination for clinical trial information for both professionals and patients.

Clinical Connection. Search for information on clinical trials conducted worldwide.

EmergingMed. Identifies clinical trials based on patient-specific diagnosis, stage, and treatment history.

European Union Clinical Trials Register. Search for protocol and results information on interventional clinical trials conducted in the EU.

International Clinical Trials Registry Platform (ICTRP). Central database containing trial registration data sets provided by global registries.

Enrollment values are based on "actual" figures rather than projected; any projected values are discarded. Where studies have multiple sites, estimates are calculated using averages across the number of sites.

Stack

Stack

Stack

“ I support Neuroute in their vision of transforming clinical research with AI. ”

Duleek Ranatunga

CEO, Founder | Pearbio

Conclusion

By integrating a multi-database approach, and using AI to conduct critical analyses, Neuroute is able to provide actionable insights on immuno-oncology studies across 8 indications and various geographies in a fraction of the time.

Where AI Meets Medicine

Explore the Future of Clinical Development with Neuroute

© Neuroute 2023

Where AI Meets Medicine

Explore the Future of Clinical
Development with Neuroute

© Neuroute 2023